

Diagnosis

For men diagnosed between January - December 2022 in England and between January - December 2021 in Wales*

50,702 men were diagnosed with prostate cancer in England in 2022

2,168 men were diagnosed with prostate cancer in Wales in 2021

27% increase compared with 39,888 men in 2021


15% increase compared with 1,886 men in 2020

This may be explained by the reporting being in the Covid-19 recovery period

* The reporting periods are different due to data availability


Age of patients diagnosed

For men diagnosed between January - December 2022 in England



● <60 ● 60-69 ● 70-79 ● ≥80

For men diagnosed between January - December 2021 in Wales



● <60 ● 60-69 ● 70-79 ● ≥80

Disease presentation

For men diagnosed between April 2020 - March 2021 in England and between April 2021 - March 2022 in Wales

19% of men presented with **metastatic** disease in both England and Wales



Number of men who underwent prostate cancer treatment

For men diagnosed between January - December 2022 in England and between January - December 2021 in Wales

7,418 men underwent a **radical prostatectomy** in England in 2022

196 men underwent a **radical prostatectomy** in Wales in 2021

27% increase compared with 5,831 men in 2021

14% decrease compared with 227 men in 2020

12,956 men underwent **radical prostate radiotherapy** in England in 2022

787 men underwent **radical prostate radiotherapy** in Wales in 2021

22% increase compared with 10,583 men in 2021

8% decrease compared with 855 men in 2020



Treatment allocation

For men diagnosed between April 2020 - March 2021 in England and between April 2021 - March 2022 in Wales

Low-risk, localised disease*



*T stage 1/2, Gleason ≤6, M/N 0 or missing

High-risk/locally advanced disease*



*T stage 3/4, Gleason ≥8, N1

Treatment outcomes (i.e genitourinary or gastrointestinal complications)

For men undergoing surgery between April 2021 - March 2022 in England and Wales



13% of men were **readmitted** within 3 months **following surgery** in England

9% of men were **readmitted** within 3 months **following surgery** in Wales



For men undergoing radical treatment between September 2019 - August 2020 in England and Wales



In England, **7%** of men experienced at least one **genitourinary** complication requiring a procedural/surgical intervention within two years after **radical prostatectomy**

In Wales, **8%**



In England, **10%** of men experienced at least one **gastrointestinal** complication requiring a procedural/surgical intervention within two years after **radical radiotherapy** in England (E) and Wales (W)


In Wales, **5%**





Change in radiotherapy regimen administered

Men starting different types of radiotherapy in England and Wales in 2019 and 2022



Note: In 2019, ultra-hypofractionated was <1%.


Note: The percentages above don't add up to 100% due to rounding.

Key:
 Conventional = 35 radiotherapy treatments over 7-8 weeks.
 Hypofractionated = 20 radiotherapy treatments over 4 weeks.
 Ultra-hypofractionated = 5 radiotherapy treatments over 1-2 weeks.

Change in type of systemic therapy administered

Men starting different types of systemic therapy in England in 2019 and 2022

Note: Data for Wales about type of systemic therapy is unavailable.



Note: In 2019, less than 1% of patients received enzalutamide, abiraterone or apalutamide.

Note: Data was available for 2022 up until 30th Sep 2022.

Key:
 Docetaxel is a type of chemotherapy whereas enzalutamide, abiraterone and apalutamide are novel hormone therapies.

Please see our glossary of terms here.

Thanks for reading the patient summary of our 2023 State of the Nation report, if you would like further detail you can access our full report here.

If you're worried about prostate cancer or prostate problems, Prostate Cancer UK offer a range of services so you can choose what works for you. Click here to have a look.